cp-55,940 has been researched along with sdb-001 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Connor, M; Hibbs, DE; Kassiou, M; Lai, F; Lane, S; Moir, M | 1 |
| Gunosewoyo, H; Ji, YY; Li, JJ; Pei, FN; Shi, JJ; Tang, J; Wang, ZL; Xie, X; Yang, F; Yu, LF | 1 |
| Chai, X; Chen, S; Jiang, BE; Jiang, X; Liang, Q; Liu, M; Lu, W; Qiu, ZL; Sun, XB; Yang, JJ; Yi, C; Yu, LF; Zhang, HK; Zhang, Q | 1 |
3 other study(ies) available for cp-55,940 and sdb-001
| Article | Year |
|---|---|
Strategies to develop selective CB
Topics: Animals; Cannabinoids; Cell Line, Tumor; Crystallography, X-Ray; Dose-Response Relationship, Drug; Indoles; Membrane Potentials; Mice; Molecular Structure; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2019 |
Introducing nitrogen atoms to amidoalkylindoles: potent and selective cannabinoid type 2 receptor agonists with improved aqueous solubility.
Topics: | 2019 |
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
Topics: Designer Drugs; Drug Discovery; Humans; Receptor, Cannabinoid, CB2; Scleroderma, Systemic; Structure-Activity Relationship | 2021 |